Statistical Power, the Belmont Report, and the Ethics of Clinical Trials

  title={Statistical Power, the Belmont Report, and the Ethics of Clinical Trials},
  author={Sara H. Vollmer and George Howard},
  journal={Science and Engineering Ethics},
Achieving a good clinical trial design increases the likelihood that a trial will take place as planned, including that data will be obtained from a sufficient number of participants, and the total number of participants will be the minimal required to gain the knowledge sought. A good trial design also increases the likelihood that the knowledge sought by the experiment will be forthcoming. Achieving such a design is more than good sense—it is ethically required in experiments when… 
University research ethics clearances: Safety nets, or a false sense of legal immunity?
Ethics reviews loom large in the world of a researcher at a university. Ethics committees review research project applications meticulously and critically. They attempt to ensure that in all projects
A review of informed consent and how it has evolved to protect vulnerable participants in emergency care research
Ethical considerations and moral obligations to safeguard vulnerable participants in research studies and preserve their autonomy are reviewed.
Clinical Trial Ethics in the Era of COVID-19 Pandemic
The cornerstones of clinical trial ethics, current publications and statements are analyzed to overcome the difficulties of pandemics with an additional focus on Turkey.
Empowering phase II clinical trials to reduce phase III failures.
This study shows how statistics explain, but do not justify, the high failure rate observed in phase III clinical trials, and suggests the simplest and most intuitive way to reduce phase III failures is to expand phase II, using an economic profile.
Empowering phase II clinical trials to reduce phase III failures
This study shows how statistics explain, but do not justify, the high failure rate observed, and how expanding phase II is the simplest and most intuitive way to reduce phase III failures.
Should end-of-life patients be enrolled as participants in clinical research? A best-fit framework synthesis.
This review provides up-to-date evidence on key challenges and ethical considerations about researching with end-of-life patients and important recommendations for clinicians, research, and ethics committee members when evaluating clinical research with people at their end of life.
Genomics, Ethics, and Compliance
This chapter begins with a review of the history of ethics and especially its relationship to research in medicine, and this is followed by a discussion of genomics and the ethical issues it elucidates, as well as compliance in medicine and the associated ethical implications.
Responsible Conduct of Human Subjects Research in Islamic Communities
A practicum project to modify an existing introduction to human subjects research for a US audience to be linguistically and culturally appropriate to Arabic-speaking-Islamic communities is described.
Optimal design of studies of influenza transmission in households. II: Comparison between cohort and case-ascertained studies
It is found that a case-ascertained study with ARi-triggered testing would be the most powerful design while a cohort design only testing household contacts with ARI was the least powerful.
Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials
This review concentrates on challenges associated with the patient recruitment process and presents current opinion and provides valuable support for planning and conducting clinical research in rare diseases.


Ethical considerations in clinical trials
It is concluded that problems of justice arise not only of the vulnerability of patients in VA hospitals hut also of the loss of the physician‐patient relationship in an RCT, and the values and preferences of the subjects should be taken into account in determining what information might be material.
Statistical power, sample size, and their reporting in randomized controlled trials.
The pattern over time in the level of statistical power and the reporting of sample size calculations in published randomized controlled trials (RCTs) with negative results is described and few trials discussed whether the observed differences were clinically important.
What are the effects of the fifth revision of the Declaration of Helsinki?
The World Medical Association's fifth revision of the Declaration of Helsinki strives to strike a balance between ensuring high ethical standards and retaining sufficient sensitivity to local circumstances to avoid thwarting research with bureaucracy.
Reporting of power and sample size in randomized controlled trials.
A large sample of articles from important journals for sample size adequacy was reviewed, noting that most trials with negative results did not have sample sizes large enough to detect a 25% or a 50% relative difference and that few trials discussed whether the observed differences were clinically important.
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.
Concern for the probability of missing an important therapeutic improvement because of small sample sizes deserves more attention in the planning of clinical trials.
When experiments go wrong: the U.S. perspective.
  • A. Capron
  • Medicine
    The Journal of clinical ethics
  • 2004
The system of local oversight is only partially effective in improving the design of experiments and the consent process in light of "unexpected (adverse) results," and it is shown that the U.S. system is far from perfect in responding when research goes wrong.
A power primer.
  • J. Cohen
  • Mathematics
    Psychological bulletin
  • 1992
A convenient, although not comprehensive, presentation of required sample sizes is providedHere the sample sizes necessary for .80 power to detect effects at these levels are tabled for eight standard statistical tests.
The Declaration of Helsinki: an update on paragraph 30
Research on human subjects is governed by a large number and wide variety of codes and policies worldwide. In Canada, the Tri-Council Policy Statement[1][1] must be adhered to by individuals and
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
This resolution is to be adopted by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013 on the theme of human rights and democracy.
Statistics, a foundation for analysis
A runaway binding assembly for skis comprising an elongated member, having opposing ends and means for connecting one end of said elongated member to a ski with the member in a desired normal